Journal Article

Skp2 targeting suppresses tumorigenesis by Arf-p53-independent cellular senescence

Lin, Hui-Kuan, Wang, Guocan, Yang, Wei-Lei, Nardella, Caterina, Teruya-Feldstein, Julie, Cordon-Cardo, Carlos, Chen, Zhenbang, Lee, Szu-Wei, Chan, Chan-Hsin, Pandolfi, Pier Paolo, Egia, Ainara, Wang, Jing, Nakayama, Keiichi I.

2010

Overview

Cellular senescence has been recently shown to have an important role in opposing tumour initiation and promotion. Senescence induced by oncogenes or by loss of tumour suppressor genes is thought to critically depend on induction of the p19 Arf –p53 pathway. The Skp2 E3-ubiquitin ligase can act as a proto-oncogene and its aberrant overexpression is frequently observed in human cancers. Here we show that although Skp2 inactivation on its own does not induce cellular senescence, aberrant proto-oncogenic signals as well as inactivation of tumour suppressor genes do trigger a potent, tumour-suppressive senescence response in mice and cells devoid of Skp2 . Notably, Skp2 inactivation and oncogenic-stress-driven senescence neither elicit activation of the p19 Arf –p53 pathway nor DNA damage, but instead depend on Atf4, p27 and p21. We further demonstrate that genetic Skp2 inactivation evokes cellular senescence even in oncogenic conditions in which the p19 Arf –p53 response is impaired, whereas a Skp2–SCF complex inhibitor can trigger cellular senescence in p53/Pten-deficient cells and tumour regression in preclinical studies. Our findings therefore provide proof-of-principle evidence that pharmacological inhibition of Skp2 may represent a general approach for cancer prevention and therapy. Senescence kills tumours Recent studies suggest that cellular senescence — an irreversible form of cell-cycle arrest — can halt tumour growth in vitro . Hui-Kuan Lin et al . now identify a previously unknown pathway that drives senescence without the involvement of most of the known mediators of senescence. Instead, it signals via the transcription factor Atf6, and the cyclin-dependent kinase inhibitors p27 and p21. The pathway is uncovered by inactivation of the proto-oncogene Skp2 , but only in the context of oncogenic signalling. Targeting the Skp2 complex pharmacologically restricts tumorigenesis by inducing cellular senescence, suggesting that such drugs may be effective in cancer prevention and therapy. Cellular senescence — an irreversible cell-cycle arrest — has been implicated in suppressing tumour formation or growth. A new cellular signalling pathway that drives senescence has now been identified. This pathway does not involve most known mediators of senescence, and instead signals via the proteins Atf4, p27 and p21. Inactivating the proto-oncogene Skp2 in the context of oncogenic signalling can induce senescence through this new pathway, indicating that drugs that target Skp2 might be useful in cancer treatment.

• Publisher: Nature Publishing Group UK,Nature Publishing Group
• Subject: 631/45/612/1243 / 631/67/581 / 631/80/509 / 692/420/755 / Activating Transcription Factor 4 - metabolism / Adenovirus E1A Proteins - genetics / Adenovirus E1A Proteins - metabolism / Aging / Animals / Apoptosis / Biological and medical sciences / Carcinogenesis, carcinogens and anticarcinogens / Care and treatment / Cell cycle / Cell Transformation, Neoplastic - drug effects / Cells / Cells, Cultured / Cellular Senescence - drug effects / Cyclin-Dependent Kinase Inhibitor p16 - deficiency / Cyclin-Dependent Kinase Inhibitor p16 - genetics / Cyclin-Dependent Kinase Inhibitor p16 - metabolism / Cyclin-Dependent Kinase Inhibitor p21 - metabolism / Cyclin-Dependent Kinase Inhibitor p27 - metabolism / Fibroblasts / General aspects / Genetic aspects / Humanities and Social Sciences / Inactivation / Male / Medical sciences / Mice / multidisciplinary / Physiological aspects / Prevention / Prostate - cytology / Prostate - metabolism / Prostatic Neoplasms - drug therapy / Prostatic Neoplasms - pathology / Prostatic Neoplasms - prevention & control / Proto-Oncogene Mas / Proto-Oncogene Proteins p21(ras) - genetics / Proto-Oncogene Proteins p21(ras) - metabolism / PTEN Phosphohydrolase - deficiency / PTEN Phosphohydrolase - genetics / PTEN Phosphohydrolase - metabolism / S-Phase Kinase-Associated Proteins - antagonists & inhibitors / S-Phase Kinase-Associated Proteins - genetics / S-Phase Kinase-Associated Proteins - metabolism / Science / Science (multidisciplinary) / SKP Cullin F-Box Protein Ligases - metabolism / Tumor suppressor genes / Tumor Suppressor Protein p53 - deficiency / Tumor Suppressor Protein p53 - metabolism / Tumors